The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.
This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).
The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.
Approximate Time to Complete: 30 minutes
Credit Available: Dec. 18, 2018 - Dec. 18, 2019
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the ongoing trials of immune checkpoint inhibitors (ICIs) alone or in combination for the management of metastatic colorectal cancer (mCRC)
- Have greater competence related to selecting the most appropriate regimen for patients with MSI-H mCRC
- Have increased knowledge regarding the Importance of testing for microsatellite instability (MSI)
- Have greater competence related to Managing immune-related adverse events (irAEs) in a patient with mCRC
- Have greater competence related to communication among the interprofessional care team so as to ensure optimal coordination of care in patients with MSI-H mCRC